(e,e,e,e)-squalene

(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.

Cross Reference

Introduction

To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with (e,e,e,e)-squalene?

(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene

MeSH term MeSH ID Detail
Persian Gulf Syndrome D018923 1 associated lipids
Hemorrhagic Septicemia, Viral D031941 1 associated lipids
Fasciitis D005208 2 associated lipids
Ossification, Heterotopic D009999 2 associated lipids
Pneumonia, Lipid D011017 2 associated lipids
Steatorrhea D045602 2 associated lipids
Exostoses, Multiple Hereditary D005097 3 associated lipids
Gallbladder Diseases D005705 3 associated lipids
Parvoviridae Infections D010322 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Per page 10 20 50 100 | Total 84

PubChem Associated disorders and diseases

What pathways are associated with (e,e,e,e)-squalene

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with (e,e,e,e)-squalene?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with (e,e,e,e)-squalene?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with (e,e,e,e)-squalene

Download all related citations
Per page 10 20 50 100 | Total 1766
Authors Title Published Journal PubMed Link
Michael-Jubeli R et al. High-temperature gas chromatography-mass spectrometry for skin surface lipids profiling. 2011 J. Lipid Res. pmid:20952798
Lama-Muñoz A et al. New hydrothermal treatment of alperujo enhances the content of bioactive minor components in crude pomace olive oil. 2011 J. Agric. Food Chem. pmid:21265536
Ellebedy AH et al. Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59. 2011 Proc. Natl. Acad. Sci. U.S.A. pmid:21270336
Morel S et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. 2011 Vaccine pmid:21256188
Sarpietro MG et al. Synthesis of n-squalenoyl cytarabine and evaluation of its affinity with phospholipid bilayers and monolayers. 2011 Int J Pharm pmid:21219999
Brasser AJ et al. Presence of wax esters and squalene in human saliva. 2011 Arch. Oral Biol. pmid:21247555
Arguedas A et al. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. 2011 Hum Vaccin pmid:21285531
Manuel O et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. 2011 Clin. Infect. Dis. pmid:21288852
Alghisi F et al. Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis. 2011 Thorax pmid:21228426
Decaro N et al. Immunogenicity and protective efficacy in dogs of an MF59â„¢-adjuvanted vaccine against recombinant canine/porcine coronavirus. 2011 Vaccine pmid:21272607
Arias JL et al. Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics. 2011 ACS Nano pmid:21275408
van den Brand JM et al. Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. 2011 J. Virol. pmid:21209108
Calabro S et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. 2011 Vaccine pmid:21215831
Javelle E et al. Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine. 2011 Vaccine pmid:21172376
Montagnani S et al. Autoimmune hemolytic anemia following MF59-adjuvanted influenza vaccine administration: a report of two cases. 2011 Ann Pharmacother pmid:21189364
Esposito S et al. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. 2011 Vaccine pmid:21199699
Nowosielski M and Hoffmann M Do the substituent effects affect conformational freedom of squalene in hopene biosynthesis? 2011 J Mol Model pmid:21562825
Hernández-García I et al. [Adverse events after administration of A/H1N1 vaccine to patients]. 2011 Med Clin (Barc) pmid:20199781
Fenoglio D et al. MF-59 adjuvant influence on the functions of gammadelta T cells in HIV-1+ adults immunized with influenza seasonal vaccine. 2011 J Prev Med Hyg pmid:22010544
Precioso AR et al. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. 2011 Vaccine pmid:21945258
Pariani E et al. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. 2011 Vaccine pmid:21974995
Andrews NJ et al. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. 2011 Vaccine pmid:21875635
Vesikari T et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. 2011 N. Engl. J. Med. pmid:21995388
Bernstein DI Vaccines for cytomegalovirus. 2011 Infect Disord Drug Targets pmid:22309618
Fox CB et al. Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions. 2011 Pharm Dev Technol pmid:20550484
Fabbiani M et al. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. 2011 Vaccine pmid:21349364
Niehaus TD et al. Identification of unique mechanisms for triterpene biosynthesis in Botryococcus braunii. 2011 Proc. Natl. Acad. Sci. U.S.A. pmid:21746901
Cheong HJ et al. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. 2011 Clin. Vaccine Immunol. pmid:21715575
Soto G et al. Acetoacetyl-CoA thiolase regulates the mevalonate pathway during abiotic stress adaptation. 2011 J. Exp. Bot. pmid:21908473
Celia C et al. Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. 2011 Expert Opin Drug Deliv pmid:22077480
Tsai TF MF59 adjuvanted seasonal and pandemic influenza vaccines. 2011 Yakugaku Zasshi pmid:22129867
Puig-Barberà J et al. MF59™-adjuvanted seasonal influenza vaccine in young children. 2011 Expert Rev Vaccines pmid:22043952
Viganò A et al. Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. 2011 Clin. Vaccine Immunol. pmid:21795458
Huijskens E et al. Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. 2011 Clin. Vaccine Immunol. pmid:21795459
Pollard AJ and Hill AV Antibody repertoire: embracing diversity. 2011 Sci Transl Med pmid:21795586
Okike IO et al. The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children. 2011 Vaccine pmid:21742005
Kowert BA and Watson MB Diffusion of organic solutes in squalane. 2011 J Phys Chem B pmid:21780767
Mackay D and Jones PJ Evaluation of methods for the determination of cholesterol absorption and synthesis in humans. 2011 Atherosclerosis pmid:21763652
Jawaid AM et al. Shape-controlled colloidal synthesis of rock-salt lead selenide nanocrystals. 2011 ACS Nano pmid:21770427
Oliaro-Bosso S et al. Characterization of the channel constriction allowing the access of the substrate to the active site of yeast oxidosqualene cyclase. 2011 PLoS ONE pmid:21811565
Bildstein L et al. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes. 2011 Eur J Pharm Biopharm pmid:21784150
Della Cioppa G et al. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. 2011 Vaccine pmid:21906647
Fox CB et al. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. 2011 Vaccine pmid:21906648
Zuccotti GV et al. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. 2011 Diabet. Med. pmid:21916971
Meyer K et al. A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. 2011 PLoS ONE pmid:21887300
Broeders NE et al. Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. 2011 Clin J Am Soc Nephrol pmid:21921153
Achiraman S et al. Increased squalene concentrations in the clitoral gland during the estrous cycle in rats: an estrus-indicating scent mark? 2011 Theriogenology pmid:21924481
Brito LA et al. An alternative renewable source of squalene for use in emulsion adjuvants. 2011 Vaccine pmid:21723355
Weyermann C et al. Initial results on the composition of fingerprints and its evolution as a function of time by GC/MS analysis. 2011 J. Forensic Sci. pmid:20707835
Launay O et al. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. 2011 J. Infect. Dis. pmid:21628666
Piccialli V et al. Isolation of a bis-iodurated tetra-THF as a trace product from the oxidation of squalene with RuOâ‚„ and its double ring expansion to a novel bis-THF-bis-THP compound. 2011 Molecules pmid:21709619
Iannazzo S Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy. 2011 J Prev Med Hyg pmid:21710816
Seubert A et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. 2011 Proc. Natl. Acad. Sci. U.S.A. pmid:21690334
Khurana S et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. 2011 Sci Transl Med pmid:21632986
Zhang LW et al. Oil components modulate the skin delivery of 5-aminolevulinic acid and its ester prodrug from oil-in-water and water-in-oil nanoemulsions. 2011 Int J Nanomedicine pmid:21556344
Lens M and Podesta Marty MH Assessment of the kinetics of the antioxidative capacity of topical antioxidants. 2011 J Drugs Dermatol pmid:21369642
Cristiani C et al. Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district. 2011 Vaccine pmid:21396903
Tabache F et al. Acute polyarthritis after influenza A (H1N1) immunization. 2011 Joint Bone Spine pmid:21444232
Sun Y et al. A reproducible in-vivo model of lymphatic malformation in rats. 2011 J. Comp. Pathol. pmid:21419420
Meier S et al. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. 2011 Vaccine pmid:21419775
Réjiba S et al. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. 2011 Nanomedicine pmid:21419876
Banzhoff A et al. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. 2011 Hum Vaccin pmid:21422814
Parretta E et al. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. 2011 Vaccine pmid:21406267
Ambike A et al. Interaction of self-assembled squalenoyl gemcitabine nanoparticles with phospholipid-cholesterol monolayers mimicking a biomembrane. 2011 Langmuir pmid:21413743
Gao J et al. Laser-induced acoustic desorption/atmospheric pressure chemical ionization mass spectrometry. 2011 J. Am. Soc. Mass Spectrom. pmid:21472571
Weschler CJ et al. Squalene and cholesterol in dust from danish homes and daycare centers. 2011 Environ. Sci. Technol. pmid:21476540
Cauda V et al. "Liquid-phase calcination" of colloidal mesoporous silica nanoparticles in high-boiling solvents. 2011 J. Am. Chem. Soc. pmid:21480591
Griffiths PD et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. 2011 Lancet pmid:21481708
Liu CL et al. The direct observation of secondary radical chain chemistry in the heterogeneous reaction of chlorine atoms with submicron squalane droplets. 2011 Phys Chem Chem Phys pmid:21455529
Inagaki YS et al. Investigation of the potential for triterpene synthesis in rice through genome mining and metabolic engineering. 2011 New Phytol. pmid:21501172
Garcia-Sicilia J et al. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. 2011 Vaccine pmid:21504774
Tsai TF et al. Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. 2011 Scand. J. Infect. Dis. pmid:21534891
Esposito S et al. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. 2011 Pediatrics pmid:21464195
Esposito S et al. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. 2011 Nephrol. Dial. Transplant. pmid:20974645
Montana M et al. Safety review: squalene and thimerosal in vaccines. 2010 Nov-Dec Therapie pmid:21176760
Bhilwade HN et al. Squalene as novel food factor. 2010 Curr Pharm Biotechnol pmid:20874681
Fragapane E et al. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. 2010 Clin. Vaccine Immunol. pmid:20810680
Esposito S et al. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major. 2010 Vaccine pmid:20888873
Khurana S et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. 2010 Sci Transl Med pmid:20371470
Lippi G et al. Vaccination, squalene and anti-squalene antibodies: facts or fiction? 2010 Eur. J. Intern. Med. pmid:20206873
Barnett SW et al. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. 2010 J. Virol. pmid:20392857
Caron J et al. Squalenoyl nucleoside monophosphate nanoassemblies: new prodrug strategy for the delivery of nucleotide analogues. 2010 Bioorg. Med. Chem. Lett. pmid:20363623
Xiong Z et al. A short total synthesis of (+)-omaezakianol via an epoxide-initiated cationic cascade reaction. 2010 Org. Lett. pmid:20218639
Durando P et al. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. 2010 Expert Opin Biol Ther pmid:20218923
Xiao L et al. The effect of squalane-dissolved fullerene-C60 on adipogenesis-accompanied oxidative stress and macrophage activation in a preadipocyte-monocyte co-culture system. 2010 Biomaterials pmid:20488530
Carmona A et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. 2010 Vaccine pmid:20600478
Caligiani A et al. Characterization of a potential nutraceutical ingredient: pomegranate (Punica granatum L.) seed oil unsaponifiable fraction. 2010 Plant Foods Hum Nutr pmid:20607413
Zhao RY et al. Cloning and characterization of squalene synthase gene from Fusarium fujikuroi (Saw.) Wr. 2010 J. Ind. Microbiol. Biotechnol. pmid:20585832
Yasuda Y et al. Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children. 2010 Adv Ther pmid:20586002
Frey SE et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. 2010 Vaccine pmid:20619382
Dosio F et al. Novel nanoassemblies composed of squalenoyl-paclitaxel derivatives: synthesis, characterization, and biological evaluation. 2010 Bioconjug. Chem. pmid:20597546
Sarpietro MG et al. Interaction of acyclovir and its squalenoyl-acyclovir prodrug with DMPC in monolayers at the air/water interface. 2010 Int J Pharm pmid:20635474
Wohlrab J et al. Interaction of epicutaneously applied lipids with stratum corneum depends on the presence of either emulsifiers or hydrogenated phosphatidylcholine. 2010 Skin Pharmacol Physiol pmid:20523109
Koohang A et al. Enantioselective inhibition of squalene synthase by aziridine analogues of presqualene diphosphate. 2010 J. Org. Chem. pmid:20545375
Kato S et al. Clinical evaluation of fullerene-C60 dissolved in squalane for anti-wrinkle cosmetics. 2010 J Nanosci Nanotechnol pmid:21137794
Lin FY et al. Mechanism of action and inhibition of dehydrosqualene synthase. 2010 Proc. Natl. Acad. Sci. U.S.A. pmid:21098670
Ali NA et al. Essential oil composition of leaves of Stachys yemenensis obtained by supercritical COâ‚‚. 2010 Nat. Prod. Res. pmid:21104527
Walker WT and Faust SN Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. 2010 Expert Rev Vaccines pmid:21105775
El Sahly H MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. 2010 Expert Rev Vaccines pmid:20923265
Waddington C et al. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age. 2010 Health Technol Assess pmid:20923610